Dr. Wu's research involves pharmacogenomics, cardiac biomarkers and clinical toxicology. With the onset of the COVID-19 pandemic, he has switch his focus towards molecular testing for the virus, antigen and antibodies after an infection and after a vaccine. Throughout his career, he has been a leader in promoting the value of clinical laboratory testing to the medical world, but especially the lay public. During the early months of the pandemic, the absence lab testing availability was directly linked to the spread of the virus.
Panel Discussion on COVID-19 Testing
COVID-19 Testing: Who, When, What? The Challenges of Testing during the Pandemic. In this panel, we will discuss how testing has evolved from the early months of the pandemic to the current unmet medical needs.
Dr. Pestano is an experienced leader in Product Development and clinical Laboratory Operations. Prior to joining Biodesix, Dr. Pestano held senior positions in Pharma Services, R&D and Project Leadership at Ventana Medical Systems, a member of the Roche Group. Dr. Pestano’s experiences are specialized in high complexity molecular diagnostics for oncology and virology and include molecular, serologic, and proteomic testing. Dr. Pestano is the co-inventor on multiple national and international patents for diagnostic tests. He has also fostered many collaborations in academia, industry, quality, and public health consortia as a part of new product development. Dr. Pestano received his Ph.D. in Molecular Cell Biology at The Graduate Center, City University of New York where his thesis focused on vaccine development for novel genetic variants of HIV-1. He conducted his post-doctoral training in Cancer Immunology and AIDS at the Dana Farber Cancer Institute, Harvard Medical School.
Real World Testing in Support of bBack to Work Programs
Panelist providing real world perspective on multiple modalities of covid testing and studies in support of back to work programs.